ClinicalTrials.gg
RecruitingNCT07678177Updated Jul 1, 2026

An Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients

An observational study in GERD (Gastroesophageal Reflux Disease), sponsored by HK inno.N Corporation. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by HK inno.N Corporation · Observational

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
5,384
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Gastroesophageal Reflux · Korea, Republic of.

Planned enrollment
6th of 19
5,384 · median 2,000
Started
2023
with 4 others
Observational
19 of 71
3 open now
Registered
66th of 71
by date
Lead sponsor
4 of 71
HK inno.N Corporation

Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, this one is the 6th largest by planned enrollment of the 19 observational ones that give a count, is one of 5 that started in 2023, is one of 19 observational ones, and was the 66th registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

8 of the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study aims to evaluate the status of AE and improvement effect of K-CAB Tab/K-CAB ODT(Tegoprazan) 50mg in patients with GERD.

Read the detailed description

This is a multi-center, prospective, non-interventional, observational study. Subjects will be prescribed in one of the two formulation groups (K-CAB Tab 50 mg or K-CAB ODT 50 mg).

03

Conditions studied

  • GERD (Gastroesophageal Reflux Disease)

Keywords

  • IN_TPZ_N03
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

University-affiliated hospitals and general hospitals that administer the investigational drug

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects over 19 years of age as of the date of consent
  2. Subjects with a total score of 8 or more in the Korean Gastroesophageal Reflux Disease Questionnaire (GerdQ) based on Visit 1
  3. Subjects who voluntarily decides to participate and agrees in writing to the consent form of the study

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have reactions and a medical history of Benzimidazole or components of the drug
  2. Subjects on Atazanavir, Nelfinavir, or Rilpivirine-containing medications
  3. Pregnant and lactating women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
5,384 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Symptom improvement rate at 4 weeks after administration of K-CAB Tablet/K-CAB ODT.

    After administering the K-CAB Tablet/K-CAB ODT for 4 weeks, heartburn and gastric acid reflux symptoms are evaluated using the symptom evaluation score, and the proportion of subjects whose sum of symptom evaluation scores has improved by more than 50%(50% Overall Responder).

    Time frame: From enrollment to the end of treatment at 4 weeks. If symptoms do not disappear at the time of 4 weeks, F/U is added for an additional 4 weeks.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jun 2027, 51 months after the start.

Of 117 observational studies under Gastroesophageal Reflux, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 134. This study's planned 51 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 1, 2026
StartActual
Mar 7, 2023
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07678177
Responsible party
Sponsor
First posted
Jul 1, 2026
Start date
Mar 7, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jul 1, 2026

Study contacts

yong an jeong
Contact
yongan.jeong@inno-n.com
82-31-5176-4673
seung gye cho
Contact
seungkye.cho@inno-n.com
82-31-5176-4676

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion